Variables Total Contact Lenses Amniotic membrane p* m (IQR) m (IQR) m (IQR) Pain         1st day 1 (0 -2) 1 (1–2) 0.5 (0 -1) 0.2 7th day 0.5 (0 -1) 1 (1–2) 0 (0 -0) 0.005* 30 days 0 (0–1) 1 (1–2) 0 (0 –0) 0.002* 90 days 2 (1–2.5) 1 (1–2) 2 (1 -3) 0.17 180 days 2 (1–5) 1.5 (1–2) 5 (4–6) 0.042* Neovascularization         1st day 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97 7th day 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97 30 days 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97 90 days 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97 180 days 1 (0–2) 1.5 (0.5–2) 0 (0 –2) 0.58 Bullae         1st day 1 (0–1) 0.5 (0 -1) 1 (0–1) 0.96 7th day 1 (0–1) 0.5 (0 -1) 1 (0–1) 0.86 30 days 0 (0–1) 0.5 (0 -1) 0 (0–0) 0.15 90 days 0 (0–1) 0.5 (0 -1) 0 (0–0) 0.15 180 days 0 (0–1) 0 (0–1) 0 (0–0) 0.43 Visual Sharpness         1st day 0.0052 (0.0052–0.0096) 0.0052 (0.0052–0.014) 0.0052 (0.0033-0.0052) 0.18 7th day 0.0052 (0.0052–0.0096) 0.0052 (0.0052–0.014) 0.0052 (0.0033-0.0052) 0.18 30 days 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.0052 (0.0052-0.014) 0.84 90 days 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.84 180 days 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.0096 (0.0033- 0.014) 0.84

Table 3: Distribution of study variables in each group after the use of contact lenses (control group) or amniotic membrane grafting (AM group) for different follow-up periods. P values correspond to the statistical comparisons between the control and the AM group. m: Median; IQR: Interquartile Range.